Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Minsk, 220072, Belarus
NCT Number: NCT04184232
Treatment of recurrent bladder cancer with dendritic cells
Looking for future studies?
Notify Me18 year–85 year
Male
Interventional
Phase 2
Minsk, 220072, Belarus
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Autologous dendritic cells primed with muc-1/wt-1 peptides
Standard treatment of bladder cancer according to the Clinical protocols
Time frame: 1 year
1 year relapse free survival
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Other Gov
Treatment of Recurrent Bladder Cancer With Autologous Monocyte-derived Dendritic Cells
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03924856
Bladder Cancer, Female Urogenital Diseases
La Jolla, California, United States
View Trial DetailsNCT04081246
Bladder Cancer, Bladder Neoplasm
Hong Kong
View Trial DetailsNCT05512377
Biliary Tract Cancer, Biliary Tract Diseases
Mobile, Alabama, United States
View Trial DetailsNCT06955910
Behavior, Behavioral Symptoms
Padova, Italy/Padova, Italy
View Trial Details